|
|
Volumn 371, Issue 9616, 2008, Pages 895-896
|
|
The ethics of non-inferiority trials
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
BETA LACTAM ANTIBIOTIC;
CYTOTOXIC AGENT;
DAPTOMYCIN;
LINEZOLID;
MACROLIDE;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
ROTAVIRUS VACCINE;
TIGECYCLINE;
TUBERCULOSTATIC AGENT;
CARDIOTOXICITY;
CLINICAL PRACTICE;
CLINICAL RESEARCH;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
INTESTINE INTUSSUSCEPTION;
LETTER;
LEUKEMIA;
MEDICAL DECISION MAKING;
MEDICAL ETHICS;
MYCOSIS;
NEPHROTOXICITY;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
ROTAVIRUS;
SOLID TUMOR;
TREATMENT OUTCOME;
VIRUS INFECTION;
CLINICAL TRIAL;
ETHICS;
NOTE;
PATIENT RIGHT;
RESEARCH ETHICS;
METHODOLOGY;
ECONOMICS;
TIME;
TUBERCULOSIS;
HEALTH CARE DELIVERY;
HEALTH CARE PLANNING;
CLINICAL TRIALS AS TOPIC;
ETHICS, RESEARCH;
HUMANS;
PATIENT RIGHTS;
RESEARCH DESIGN;
ANTITUBERCULAR AGENTS;
TIME FACTORS;
TUBERCULOSIS;
DELIVERY OF HEALTH CARE;
HEALTH RESOURCES;
|
|
EID: 40649107375
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(08)60407-9 Document Type: Letter |
|
Times cited : (6)
|
|
References (5)
|
